Luvent FX


Montelukast Sodium eq. to Montelukast  –  10 mg
Fexofenadine Hydrochoride    –     120 mg


Each box contain10 Alu-Alu strips of 10 Tablets.

Product Description

Luvent Fx contains Montelukast and Fexfenadine.

Montelukast is a leukotriene receptor antagonist (LTRA). It is mainly used for the treatment of seasonal asthma and symptoms associated with seasonal allergies. It can be taken with or without food. It is also used in many conditions like exercise induced bronchospasm, allergic rhinitis or urticaria.

Fexofenadine is third generation anti-histamine which has a ability to pass through blood brain barrier. It also causes sedation.

  • Shortness of breathing caused by asthma
  • Prevention of wheezing
  • Breathing problems occurring during exercise
  • Reduces the use of inhaler
  • Seasonal allergic symptoms which includes sneezing, runny nose, itchy throat, or itchy, watery eyes
  • Hives and skin itching
Mechanism of action

Montelukast is a leukotriene receptor antagonist (LTRA). It causes antagonism action on leukotriene D4 (LTD4) which is present on cysteinyl leukotriene receptor and Cys LT 1 in human airway. It blocks the action produced by LTD4 which protects airway edema, secretion of thick mucus and smooth muscle contraction.
It can also provide alternative therapy to anti-inflammatory medications for chronic asthma management and exercise induced bronchospasm.
It produces its action by competing with free histamine for binding at H-1 receptor which is present in GI tract and bronchial smooth muscle. This  causes blocking of actions of endogeneous histamine and produces relief in negative symptoms caused by histamine.


It gets rapidly absorbed by the body. The mean plasma concentration is achieved in 3 to 4hrs. The oral bioavailability is about 64%. The bioavailability of the drug is not influenced by meals.
About 99% of the drug is bound to plasma proteins. The volume of distribution is about 8-11 liters. The metabolism of the drug is liver by CYP3A4, 2C8 and 2C9.
The plasma clearance of montelukast is 45ml/min. Most of the drug is excreted through bile. The plasma half life is 2.7-5.5 hrs.
After oral administration it is about 33% absorbed in the body
About 60-70% of the drug is bound to plasma protein. The metabolism of the drug is through cytochrome P450 3A4 and by intestinal micro flora.
The drug is excreted through feces and urine. The elimination half life is 14.4hrs

  • Hypersensitivity to any of the product
  • Patients with hypersensitivity to such drugs
  • Renal disease
  • Pediatric patients with renal impairment
  • Hypersensitivity to fexofenadine or any of the ingredient present
  • Rare cases of hypersensitivity reactions with manifestations such as angioedema, flushing, dyspepsia and chest tightness.
  • Long treatment can cause somnolence, fatigue, and asthenia
  • Patient should not involved in those task which require complete concentration
  • Patients with predisposing factors of urinary retention
  • Use in pregnant patients when clearly needed
  • Reversal of bronchospasm in acute asthma attacks
  • Exacerbations of asthma after exercise